Hexima (ASX:HXL) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hexima Current Accrued Expense?

Hexima's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Hexima Current Accrued Expense Historical Data

The historical data trend for Hexima's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Current Accrued Expense Chart

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial										-	-	-	-	-

Hexima Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Hexima Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Hexima's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.